ADVANCED SCIENTIFIC DISCOURSE ON THE HOLISTIC INTEGRATION OF PHARMACOGENOMICS, PERSONALIZED MEDICINE, AND PATIENT-CENTERED THERAPEUTIC PARADIGMS IN MITIGATING DRUG-RELATED ADVERSE EVENTS, TOXICOLOGICAL MANIFESTATIONS, CONTEMPORARY PHARMACOVIGILANCE BARRIERS, HIGH-RISK PHARMACOLOGICAL AGENTS AND PHARMACOTHERAPY OPTIMIZATION

Nodar Sulashvili[1,2,3], Otar Gerzmava[1], Margarita Beglaryan[1], Nana Gorgaslidze[1], Luiza Gabunia[1],Naira Chichoyan[4], Nato Alavidze[5], Natia Kvizhinadze[1], Nino Abuladze[5], Ketevani Gabunia[5], Marika Sulashvili[1], Lela Grigolia[6], Kakhaber Robakidze[6,7],Marina Giorgobiani[1], Irine Zarnadze[1], Shalva (Davit) Zarnadze[1]

[1]Tbilisi State Medical University, Georgia,
[2]International School of Medicine at Alte University, Georgia,
[3]Georgian National University SEU, Georgia,
[4]Yerevan State Medical University After Mkhitar Heratsi, Armenia
[5]Tsereteli State University, Georgia, [6]Caucasus International University; Tbilisi, Georgia,
[7]National Health Center Named After Academician O. Gudushauri
n.sulashvili@ug.edu.ge

The evolving landscape of modern therapeutics demands a paradigm shift toward holistic patient care that integrates pharmacogenomics, personalized medicine, and patient-centered approaches to address the growing challenge of drug-related adverse events and toxicological risks. This scientific discourse examines the critical intersection of these disciplines in optimizing pharmacotherapy outcomes while overcoming contemporary pharmacovigilance barriers. The analysis presents a comprehensive framework for mitigating risks associated with high-risk pharmacological agents through precision medicine strategies that account for genetic variability, physiological parameters, and individual patient profiles. At the core of this investigation lies the application of pharmacogenomic principles to predict and prevent adverse drug reactions, with particular emphasis on polymorphic drug-metabolizing enzymes and transporter proteins that significantly influence pharmacokinetic and pharmacodynamic outcomes. The study evaluates how next-generation sequencing and bioinformatics tools can be leveraged to identify genetic markers associated with hypersensitivity reactions, dose-dependent toxicities, and therapeutic failures. Concurrently, it explores the integration of these genomic insights with clinical factors—including comorbidities, polypharmacy patterns, and demographic variables—to develop truly personalized therapeutic regimens. The discourse critically assesses current pharmacovigilance systems, identifying limitations in spontaneous reporting mechanisms and proposing enhanced surveillance models incorporating real-world evidence and artificial intelligence-driven signal detection. Special attention is given to high-risk medication classes such as antineoplastics, anticoagulants, and psychotropic agents, where the margin between therapeutic benefit and potential harm is narrow. The analysis demonstrates how patient-centered care models, incorporating shared decision-making and digital health technologies, can improve medication adherence and safety monitoring. This work further examines innovative strategies for pharmacotherapy optimization, including dynamic dosing algorithms, therapeutic drug monitoring 2.0 approaches, and biomarker-guided treatment protocols. The synthesis of these approaches presents a transformative opportunity to reduce the global burden of preventable adverse drug events while maximizing therapeutic efficacy. By bridging the gap between genomic science and clinical practice, this research contributes to the development of precision pharmacotherapy frameworks that enhance patient safety, improve treatment outcomes, and pave the way for a new era in evidence-based, individualized medicine. The findings underscore the imperative for healthcare systems to adopt integrated, multidisciplinary approaches that harmonize cutting-edge science with compassionate patient care in the pursuit of optimal pharmacological outcomes.